Summary by Futu AI
TENSENG PHARMACEUTICALS B-B ANNOUNCED ON FEBRUARY 13, 2024 U.S. EASTERN TIME (I.E. FEBRUARY 14, HONG KONG TIME) THAT IT HAS REACHED A NUMBER OF TRANSACTIONS WITH THE VBI CONTRACTOR, INCLUDING THE BRII-179 PURCHASE AGREEMENT, THE TECHNOLOGY TRANSFER SUPPLEMENTAL AGREEMENT, THE VBI-1901 LICENSE AGREEMENT AND THE REHOVOT ASSET PURCHASE AGREEMENT. The transaction involves the permanent acquisition of BRII-179 related intellectual property rights worldwide, as well as the exclusive license to develop and commercialize VBI-1901 in the Asia-Pacific region (excluding Japan). IN ADDITION, THE COMPANY WILL ACQUIRE ASSETS AND LIABILITIES ASSOCIATED WITH THE REHOVOT FACILITY. As a transaction fee, Tengsheng Pharmaceutical will issue secured promissory notes. These transactions are considered to be disclosable transactions and are subject to the Notices and...Show More